Lupin clarifies on reports of ban on Gluconorm

The Delhi High Court has remanded the said order to Drugs Technical Advisory Board to examine the issue as per the Supreme Court’s direction.

Feb 28, 2019 09:02 IST India Infoline News Service

Lupin in its filing to the exchanges clarified on media reports of the government’s ban on the company’s anti-diabetic drug ‘Gluconorm’ stating that the litigation was a non-material one.

The company also stated that the Delhi High Court has set aside the order for the same case and remanded the said order to Drugs Technical Advisory Board to examine the issue as per the Supreme Court’s direction.
Lupin Ltd is currently trading at Rs771 up by Rs3.3 or 0.43% from its previous closing of Rs767.70 on the BSE.
The scrip opened at Rs765.80 and has touched a high and low of Rs772.15 and Rs765.80 respectively.

Related Story